[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombosis-deep-vein\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombosis-deep-vein":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100621599","safety-of-perioperative-anticoagulation-management-in-people-with-active-cancer-undergoing-cancer-related-surgery-or-procedures-ace-high-study-100621599",false,"NCT07372716","Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)","Active Cancer Patients Having Cancer Related Invasive Procedures or Surgery and Needing Perioperative Management of Anticoagulation Therapy (ACE-HIGH): A Prospective Management Cohort Study","ACE-HIGH","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Prescribed a Direct Oral Anticoagulant (DOAC), warfarin (International Normalized Ratio (INR) target 2.0-3.0) or Low Molecular Weight Heparin (LMWH) (75-100% weight-based therapeutic dosing) for stroke prevention in Atrial Fibrillation (AF) or the treatment of Venous Thromboembolism (VTE). Eligible DOAC regimens include full-dose (therapeutic) DOAC regimens appropriate for age and renal function. Eligible DOAC regimens include:\n\n  i. Apixaban 10 mg po BID (VTE) ii. Apixaban 5 mg po BID (AF or VTE) iii. Apixaban 2.5 mg po BID (AF) iv. Rivaroxaban 15 mg po BID (VTE) v. Rivaroxaban 20 mg po OD (AF or VTE) vi. Rivaroxaban 15 mg po OD (AF only) vii. Edoxaban 60 mg po OD (AF or VTE) viii. Edoxaban 30 mg po OD (AF or VTE) ix. Dabigatran 150 mg po BID (AF or VTE) x. Dabigatran 110 mg po BID (AF)\n* Has active cancer, defined as:\n\n  i. cancer diagnosed within 6 months ii. recurrent, regionally advanced, or metastatic cancer iii. cancer for which treatment had been administered within 6 months before enrolment iv. hematologic cancer that is not in remission v. Patients who are felt to likely have active cancer based on clinical\u002Fimaging characteristics but are awaiting tissue confirmation and are scheduled for a biopsy procedure are eligible for trial inclusion\n* Is undergoing a planned cancer-related inpatient or outpatient invasive procedure or cancer surgery (to diagnose, treat or palliate cancer; at investigator's discretion)\n* Interruption of anticoagulation therapy for the planned procedure is required.\n\nExclusion Criteria:\n\n* Presence of any mechanical prosthetic heart valve\n* Known pregnancy or breastfeeding\n* Severe renal insufficiency (Creatinine Clearance (CrCl) \\\u003C 30 mL\u002Fmin or \\\u003C 25 mL\u002Fmin for Apixaban users)\n* Condition that might impair adherence to the study protocol (e.g., cognitive impairment, geographic inaccessibility) as determined by the treating physician\n* Allergy to heparin or a history of (Heparin Induced Thrombocytopenia (HIT)\n* More than one surgery\u002Fprocedure planned during the study period\n* Previous study participation\n* Inability to provide informed consent","ALL","18 Years",{"count":20,"type":21},700,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to help find how safe current practices are when managing blood thinners in people with cancer who are having surgery or medical procedures. Investigators will also measure how often bleeding or clotting problems happen in this setting. The goal is to use this information to improve future care and reduce these risks for patients. This study will determine whether contemporary practices can be safely applied to cancer patients, and also evaluate the blood thinner level left over in patient's body at the time of surgery.",[27,28,29,30,31,32],"Thrombosis","Cancer","Thrombosis, Deep Vein","Atrial Fibrillation (AF)","Venous Thromboembolic Event","Bleeding",[34,35,28,36,37,38],"thrombosis","Atrial fibrillation","Anticoagulant Interruption","VTE","bleeding","NOT_YET_RECRUITING","2026-02-05",{"date":42,"type":43},"2026-02-06","ACTUAL",{"date":45,"type":21},"2026-03",{"date":47,"type":21},"2031-12",{"name":49,"class":50},"Ottawa Hospital Research Institute","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100428700","phase-2-perivenous-dexamethasone-therapy-examining-reduction-of-inflammation-after-thrombus-removal-to-yield-benefit-in-acute-femoropopliteal-dvt-100428700","NCT04862468","Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT","Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT (DEXTERITY-AFP)","DEXTERITY-AFP","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form prior to receiving any non-standard of care, protocol-specific procedures.\n2. Stated willingness to comply with all study procedures including completion of questionnaires and follow-up visits and availability for the duration of the study.\n3. Male or female, aged 18 to 89 years.\n4. For females of reproductive potential: use of highly effective contraception (abstinence is acceptable) for at least 1 month prior to study treatment (unless they had given birth within the 1 month prior to study treatment), and agreement to use such a method for at least 30 days after study treatment.\n5. Onset of acute DVT symptoms of 14 days or less prior to initial intervention in the study limb.\n6. Ability to take oral medication and be willing to adhere to the prescribed anti-coagulant regimen.\n7. Post-procedural prescription for at least 28 days low molecular weight heparin followed by therapeutic anticoagulant of investigator's choice for 12 months minimum as part of post-interventional medication regimen.\n8. Minimum of 28 days of prescribed antiplatelet agent (aspirin or P2Y12 inhibitor) for patients receiving stents.\n9. DVT located in any of the major femoropopliteal veins (common femoral, femoral, and\u002For popliteal above the tibial plateau), with possible extension downstream into the iliac veins.\n10. Successful recanalization of the target vein with removal of acute thrombus.\n\nExclusion Criteria:\n\n1. Current enrollment in another non-registry clinical study of systemic drug therapy or another device study that has not completed its primary endpoint, including prior enrollment in this study. Concurrent enrollment in registry studies of approved devices or drugs are acceptable.\n2. Lack of capability of understanding the nature, significance and implications of the clinical trial.\n3. Body Mass Index between 40 kg\u002Fm2 and 45 kg\u002Fm2, with significant comorbidity which, in the Investigator's discretion, could impair follow-up or study outcomes.\n4. Body Mass Index \\> 45 kg\u002Fm2.\n5. Non-ambulatory status prior to DVT occurrence.\n6. In the study leg: current established PTS (Villalta ≥ 5 for more than 14 days), current known symptomatic deep venous insufficiency for more than 14 days, or previous symptomatic DVT within the last 365 days.\n7. In the contralateral (non-study) leg: symptomatic DVT that, in the opinion of the operating physician, will require a subsequent open or endovascular surgery in the following 30 days.\n8. In cases with symptoms of limb-threatening circulatory compromise, ankle-brachial index \\\u003C0.4, absolute ankle pressure \\\u003C50 mmHg or absolute toe pressure \\\u003C30 mmHg.\n9. Pulmonary embolism (PE) defined as either massive (systolic blood pressure \\\u003C 90 mmHg and\u002For patient on IV vasoactive medication to support blood pressure), or intermediate high-risk PE, as defined by the European Society Guideline on management of PE. Low-risk PE and\u002For intermediate low-risk PE can be enrolled.\n10. Inability to tolerate contemporary venous intervention procedure due to severe dyspnea or acute systemic illness.\n11. Allergy or hypersensitivity to any drugs planned for use in the case (including dexamethasone sodium phosphate, iodinated contrast, low molecular-weight heparin, or recombinant tissue plasminogen activator, rtPA, if planned), except for mild-moderate contrast allergies for which steroid pre-medication can be used.\n12. History of, or active heparin-induced thrombocytopenia (HIT).\n13. Hemoglobin \\\u003C 8.0 g\u002Fdl.\n14. INR \\> 1.6 before starting anticoagulation.\n15. Platelets \\\u003C 100,000\u002Fml.\n16. Severe renal impairment (estimated glomerular filtration rate \\\u003C 30 ml\u002Fmin).\n17. Active bleeding, recent (\\\u003C 1 mo) GI bleeding, severe liver dysfunction, bleeding diathesis.\n18. Recent (\\\u003C 3 mo) internal eye surgery or hemorrhagic retinopathy.\n19. Recent (\\\u003C 10 days) major surgery, trauma, cardiopulmonary resuscitation, or other invasive procedure which, in the Investigator's discretion, could impair follow-up or study outcomes.\n20. Obstetrical delivery \\\u003C72 hours prior to procedure.\n21. Hemorrhagic stroke within the last 365 days.\n22. Intracranial\u002Fintraspinal bleed within the last 365 days.\n23. Intracranial\u002Fintraspinal tumor within the last 365 days.\n24. Intracranial\u002Fintraspinal vascular malformation within the last 365 days.\n25. Intracranial\u002Fintraspinal aneurysm within the last 365 days.\n26. Active symptomatic COVID-19 infection that, in the Investigator's discretion, could impair follow-up or study outcomes.\n27. Severe hypertension on repeated readings (systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 105 mmHg). This can be treated, and blood pressure must be stable before venous access is obtained (systolic blood pressure \\\u003C140 mmHg).\n28. Pregnant or breastfeeding.\n29. Life expectancy \\\u003C 2 years (e.g. due to active cancer).\n30. Major thrombus of the inferior vena cava (IVC) (occlusive or near-occlusive) extending at least one centimeter above the common iliac confluence.\n31. Inability to obtain venous access.\n32. Inability to recanalize the target vein segment with less than 30% residual obstruction due to thrombus.\n33. History of ipsilateral venous stent.\n34. DVT target length intended for drug treatment exceeds 50 cm.","89 Years",{"count":61,"type":21},80,[63],"PHASE2","This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.",[29,66],"Iliofemoral; Thrombosis","RECRUITING","2025-07-01",{"date":70,"type":43},"2025-07-04",{"date":72,"type":43},"2021-10-29",{"date":74,"type":21},"2028-02-01",{"name":76,"class":77},"Mercator MedSystems, Inc.","INDUSTRY",17,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100418657","phase-4-pre--vs-postoperative-thromboprophylaxis-for-liver-resection-100418657","NCT04731558","Pre- Vs Postoperative Thromboprophylaxis for Liver Resection","Pre- Vs Postoperative Thromboprophylaxis for Liver Resection - a Prospective, Multicenter, Randomized Controlled Trial","PREPOSTEROUS","Inclusion Criteria:\n\n* All patients undergoing liver resection\n\nExclusion Criteria:\n\n* Patient on anticoagulative medication (heparin, low-molecular weight heparin, warfarin, direct oral anticoagulants) during last month pre-surgery\n* Emergency operation (e.g. for trauma or infection)\n* Age \\\u003C 18 years\n* Allergy or other contraindication to planned low-molecular weight heparin\n* Inability to give written informed consent\n* Liver resection not performed (removed from analyses after randomization)",{"count":88,"type":21},1012,[90],"PHASE4","Thromboprophylaxis for liver surgery can be commenced either preoperatively or postoperatively. Despite a clear trade-off between thrombosis and bleeding in liver surgery patients, there is no international consensus when thrombosis prophylaxis should be commenced in patients undergoing liver surgery. As far as we know, there are no prospective randomized trials in this field, and current guidelines are unfortunately based on very low quality evidence, that is, a few retrospective studies and expert opinion. Both American and European thromboprophylaxis guidelines for abdominal cancer surgery support the preoperative initiation of thromboprophylaxis, but these guidelines do not specifically address the increased bleeding risk associated with liver surgery. On the contrary, Dutch guidelines recommend postoperative thromboprophylaxis only, because of lack of evidence for preoperative thromboprophylaxis. Traditionally, many liver surgery units have been reluctant in using preoperative thromboprophylaxis due to the potentially increased risk of bleeding complications. Enhanced Recovery After Surgery (ERAS) Society Guidelines recommend preoperative thromboprophylaxis in liver surgery, but the guidelines provide no supporting evidence for this recommendation. Overall, the amount of evidence is scarce and somewhat contradictory in this clinically relevant field of thromboprophylaxis in liver surgery. The aim of this study is to compare pre- and postoperatively initiated thromboprophylaxis regimens in liver surgery in a randomized controlled trial.",[93,94,29,95,32],"Liver Cancer","Surgery","Embolism, Pulmonary","2025-02-12",{"date":98,"type":43},"2025-02-14",{"date":100,"type":43},"2021-02-10",{"date":102,"type":21},"2027-03",{"name":104,"class":50},"Helsinki University Central Hospital",7]